Brazil’s ANS Expands Mandatory Coverage to PARP Inhibitors and Atopic Dermatitis Biologic

Media partner

POLICY & MARKETS · IMMUNOLOGY & INFLAMMATION · MAY 24, 2026 · LATIN AMERICA

Three additions to Brazil’s mandatory private-plan formulary, approved by the Agencia Nacional de Saude Suplementar (ANS) in the second quarter of 2026, extend precision medicine coverage obligations to a new oncology indication and introduce the first biologic for atopic dermatitis into the supplementary health system’s required benefit set. The decisions affect olaparib monotherapy for BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC), osimertinib combined with chemotherapy for EGFR-positive non-small cell lung cancer (NSCLC), and lebriquizumab for severe atopic dermatitis — the last following a price reduction by the manufacturer, according to ANS announcements.

System Implications

Brazil’s supplementary health system covers a substantial enrolled population, and ANS rol inclusions carry binding force: private health plans operating under ANS regulation are legally required to cover listed therapies. The three approvals collectively extend the system’s precision medicine perimeter — olaparib and osimertinib are biomarker-gated therapies requiring confirmed molecular status before prescription, per the agency’s coverage criteria as reported in ANS communications.

The inclusion of lebriquizumab, an IL-13 antagonist developed by Eli Lilly for severe atopic dermatitis, marks the first biologic for that indication to enter the mandatory rol, according to Source 1. Its approval was conditioned on a price adjustment by the manufacturer, a detail that signals the ANS’s willingness to use pharmacoeconomic negotiation as a lever for formulary entry rather than declining coverage outright.

The osimertinib-plus-chemotherapy combination adds a second-line or combination-use dimension to a molecule already present in oncology practice, though the specific coverage criteria and line-of-therapy restrictions applicable under the ANS decision are not fully detailed in the available source material. Further data is needed to assess the precise patient eligibility thresholds ANS has established for this indication.

Patient Access

For patients with BRCA-mutant mCRPC enrolled in private health plans, the olaparib inclusion means access to an oral PARP inhibitor through mandatory reimbursement — a modality that previously required either out-of-pocket expenditure or litigation against insurers to compel coverage, according to the ANS announcement. The shift from contested access to formulary entitlement is operationally significant for this patient population.

Lebriquizumab’s inclusion addresses a condition — severe atopic dermatitis — where biologic therapy has been available in other markets but absent from Brazil’s mandatory private coverage framework. Patients who meet the severity criteria established by ANS would, under the new rol, be entitled to coverage without plan-by-plan negotiation.

The biomarker requirements attached to the oncology approvals introduce a prerequisite layer: patients must have confirmed BRCA mutation status or EGFR-positive status, respectively, before coverage obligations are triggered. This does not diminish the access gain, but it does mean that diagnostic access — molecular testing availability and turnaround — becomes a practical bottleneck for realizing the formulary benefit at the patient level.

Industry and Payer Implications

For AstraZeneca, the olaparib and osimertinib inclusions secure reimbursement pathways within the supplementary health segment, which operates independently of Brazil’s public SUS system. Private plan coverage does not automatically extend to SUS, but ANS rol status establishes commercial precedent and may support parallel access negotiations in the public channel — though the input signal does not confirm any such linkage explicitly.

Eli Lilly’s price concession on lebriquizumab to achieve ANS approval establishes a data point for how the agency approaches novel biologics in non-oncology indications: market entry is available, but conditioned on pharmacoeconomic adjustment. This pattern, if it persists, would likely require manufacturers of pipeline biologics targeting the Brazilian supplementary market to model price flexibility into their access strategies from early in the regulatory timeline.

Private health plans face an immediate operational requirement: formulary updates, network contracting with dispensing pharmacies or specialty providers, and actuarial recalibration to absorb the cost of three newly mandated therapies. ANS rol inclusions do not come with transition grace periods that suspend coverage obligations — plans are expected to comply with the updated rol on the effective dates established by the agency. The specific compliance deadlines for these three approvals are not detailed in the available source material, and plans should consult the official ANS gazette publications directly.

Regulatory and Legal Considerations

The ANS decisions reported here are confirmed regulatory approvals, not proposals subject to public comment, according to Source 1 and the linked ANS official communications. No litigation or enforcement action related to these specific inclusions is referenced in the available source material.

Brazil’s rol system has historically been the subject of judicial disputes when plans deny coverage for listed therapies. The formal inclusion of olaparib, osimertinib, and lebriquizumab in the mandatory benefit list would, under established Brazilian health law, provide patients and providers with a direct legal basis to compel coverage — reducing, though not eliminating, the litigation burden that has characterized access to high-cost therapies in the supplementary system.

The lebriquizumab approval’s dependence on a manufacturer price reduction introduces a regulatory precedent worth monitoring: if ANS formalizes price negotiation as a standard condition for biologic rol inclusion, the agency’s role would expand from coverage arbiter to active pricing counterparty — a shift with implications for how manufacturers structure market entry dossiers.

Counterpoint

The principal counterargument is that mandatory rol inclusion does not resolve the actuarial and network-readiness gaps that determine whether coverage translates into actual patient access. Private health plans in Brazil operate under financial constraints, and the simultaneous addition of three high-cost therapies — two oncology agents with biomarker prerequisites and a novel biologic — creates a compounding cost-absorption challenge that smaller regional plans may struggle to manage within standard premium adjustment cycles. If plans lack contracted specialty pharmacy networks capable of dispensing olaparib or lebriquizumab, or if molecular testing infrastructure is unevenly distributed across plan networks, the formulary entitlement exists on paper while access remains functionally delayed. The ANS announcements confirm the coverage mandate; they do not confirm that the operational infrastructure required to fulfill it is uniformly in place.

Strategic Outlook

The lebriquizumab approval’s price-concession mechanism may suggest an emerging ANS framework in which pharmacoeconomic negotiation — rather than outright rejection — becomes the standard resolution for high-cost therapies that do not meet initial cost-effectiveness thresholds. If this reading is correct, manufacturers with pipeline assets targeting the Brazilian supplementary market would face a structured negotiation expectation rather than a binary approval decision.

For the oncology segment, the BRCA-gated olaparib inclusion could contribute to increased demand for companion diagnostic testing within private plan networks, as coverage eligibility depends on confirmed mutation status. Whether private plans will be required to cover the associated molecular diagnostics under existing rol provisions is a question the available signal does not resolve.

Closing Insight

The more consequential long-term signal in these three decisions may not be the therapies themselves but the diagnostic prerequisite they embed: as biomarker-gated therapies accumulate in the ANS rol, molecular testing access becomes a de facto coverage condition — and the plans, not the manufacturers, bear the network-readiness risk of closing that gap.